TolaSure topical gel - BioMendics
Alternative Names: BM-3103; TolaSure; TolaSure topical gelLatest Information Update: 01 Nov 2023
At a glance
- Originator BioMendics
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antifungals; Antivirals; Small molecules
- Mechanism of Action Bacterial biofilm inhibitors; Bacterial growth inhibitors; Intermediate filament protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Wounds
- Phase I Epidermolysis bullosa
- Preclinical Bacterial infections; Burns; Dermatitis; Ichthyosis; Methicillin-resistant Staphylococcus aureus infections; Mycoses; Psoriasis; Scleroderma; Skin ulcer
Most Recent Events
- 30 Oct 2023 BioMendics plans a phase II trial for Epidermolysis bullosa (Topical) in 2024
- 22 Jun 2023 BioMendics completes a phase I trial in Epidermolysis bullosa in USA (Topical) (NCT05062070)
- 01 May 2023 TolaSure topical gel - BioMendics receives Orphan Drug status for Epidermolysis bullosa in USA